Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
El-Sadr, W. M.; Grund, B.; Neuhaus, J.et al.
2008 • In Annals of Internal Medicine, 149 (5), p. 289-99
[en] BACKGROUND: Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy. OBJECTIVE: To determine whether reinitiating continuous antiretroviral therapy in patients who received episodic treatment reduces excess risk for opportunistic disease or death. DESIGN: Randomized, controlled trial. SETTING: Sites in 33 countries. PATIENTS: 5472 HIV-infected individuals with CD4(+) cell counts greater than 0.350 x 10(9) cells/L enrolled from January 2002 to January 2006. INTERVENTION: Episodic or continuous antiretroviral therapy initially, followed by continuous therapy in participants previously assigned to episodic treatment. MEASUREMENTS: Opportunistic disease or death was the primary outcome. RESULTS: Eighteen months after the recommendation to reinitiate continuous therapy, mean CD4+ cell counts were 0.152 x 10(9) cells/L (95% CI, 0.136 to 0.167 x 10(9) cells/L) less in participants previously assigned to episodic treatment (P < 0.001). The proportion of follow-up time spent with CD4+ cell counts of 0.500 x 10(9) cells/L or more and HIV RNA levels of 400 copies/mL or less was 29% for participants initially assigned to episodic therapy and 66% for those assigned to continuous therapy. Participants who reinitiated continuous therapy experienced rapid suppression of HIV RNA levels (89.7% with HIV RNA levels < or =400 copies/mL after 6 months), but CD4+ cell counts after 6 months remained 0.140 x 10(9) cells/L below baseline. The hazard ratio (episodic versus continuous treatment) for opportunistic disease or death decreased after the recommendation to reinitiate continuous therapy (from 2.5 [CI, 1.8 to 3.5] to 1.4 [CI, 1.0 to 2.0]; P = 0.033 for difference). The residual excess risk was attributable to failure to reinitiate therapy by some participants and slow recovery of CD4+ cell counts for those who reinitiated therapy. LIMITATION: Follow-up was too short to assess the full effect of switching from episodic to continuous antiretroviral therapy. CONCLUSION: Reinitiating continuous antiretroviral therapy in patients previously assigned to episodic treatment reduced excess risk for opportunistic disease or death, but excess risk remained. Episodic antiretroviral therapy, as used in the SMART study, should be avoided.
Disciplines :
Immunology & infectious disease
Author, co-author :
El-Sadr, W. M.
Grund, B.
Neuhaus, J.
Babiker, A.
Cohen, C. J.
Darbyshire, J.
Emery, S.
Lundgren, J. D.
Phillips, A.
Neaton, J. D.
Other collaborator :
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation
Language :
English
Title :
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
Publication date :
2008
Journal title :
Annals of Internal Medicine
ISSN :
0003-4819
eISSN :
1539-3704
Publisher :
American College of Physicians American Society of Internal Medicine, Philadelphia, United States - Pennsylvania
Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96. [PMID: 17135583]
Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-63. [PMID: 17721103]
Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13:177-87. [PMID: 18505169]
Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW. SMART Study Group. The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr. 2008;47:185-93. [PMID: 17971716]
Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145-55. [PMID: 18476293]
Lifson AR, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, et al. INSIGHT Cause of Death Writing Group. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials. 2008;9:177-85. [PMID: 18547904]
Hennessey KA, Giorgi JV, Kaplan AH, Visscher BR, Gange S, Margolick JB, et al. AIDS onset at high CD4+ cell levels is associated with high HIV load. AIDS Res Hum Retroviruses. 2000;16:103-7. [PMID: 10659049]
Bogaards JA, Weverling GJ, Geskus RB, Miedema F, Lange JM, Bossuyt PM, et al. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis. Antivir Ther. 2003;8:43-50. [PMID: 12713063]
CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004;18:51-8. [PMID: 15090829]
UK Collaborative HIV Cohort Study. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717-21. [PMID: 17690569]
Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22:841-8. [PMID: 18427202]
Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, et al. CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-9. [PMID: 16514305]
Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-41. [PMID: 16908797]
Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, et al. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Hum Retroviruses. 2002;18:909-16. [PMID: 12230934]
Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr. 2005;39:523-9. [PMID: 16044002]
Boschi A, Tinelli C, Ortolani P, Arlotti M. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection. J Antimicrob Chemother. 2006;57:520-6. [PMID: 16387747]
Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451-8. [PMID: 16890831]
Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. EuroSIDA Study Group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370:407-13. [PMID: 17659333]
Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. ATHENA, Netherlands National Observational Cohort Study. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007;45:183-92. [PMID: 17414934]
Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133-44. [PMID: 18476292]
Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17:1907-15. [PMID: 12960823]
Kuller LH, for the SMART Study Group. Elevated levels of IL-6 and D-dimer are associated with increased risk of death in patients with HIV [Abstract]. Proceedings of the 15th Annual Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 3-6 February 2008. Abstract no. 139.